|
Amino acid
precursors in depression are safe with
any prescription drug, but they can cause the side
effects of the prescription drugs to be
displayed in depression treatment. Any side effect associated
with the drug can be triggered during
depression treatment. For
example, a patient was taking an SSRI
for depression which had the side effect of malignant
neuroleptic syndrome. As the
amino acids were started for depression, the patient
developed new onset malignant
neuroleptic syndrome. When drug side
effects occur, it is necessary to manage
the situation as you would with any
other prescription drug side effect,
which in general means decreasing or
stopping the drug not the amino acid.
With
regards to pregnancy there is nothing in
the literature indicating that the amino
acid precursors are a problem. Nor is
there anything in the literature
indicating studies have been performed
indicating they are safe. In this light
it is recommended that amino acid
precursors not be used in the first
trimester of pregnancy.
Its no secret, NeuroResearch Clinics uses the nutrients 5-HTP, tyrosine, levodopa,
and cysteine to treat medical
patients in order to get these
results. Proper
use of these simple ingredients in
medical treatment is not simple.
From time to time a patient will
say, "Why do I want to take that, I
can go to a health food store and
buy it?" People off the street
buying in a health food store is
like going to an art store and
buying a bunch of oil paints then
going home and expecting to paint
like a mater artist even though
there was no previous painting
experience. These nutrients have
tremendous potential due to their
chemical properties. This potential
is only fully realized in the hands
of the trained professional using
neurotransmitter testing. Treatment
is not just giving a nutrient pill, it is the whole medical management approach doctors are trained in to insure that that treatment is on track in order to get symptoms under control.
The Peer Reviewed Research
of NeuroResearch Clinics
The neurotransmitter treatment research findings of NeuroResearch Clinics
have not been ignored. The University of
Minnesota Medical School is writing a series of
papers on the neurotransmitter testing research of NeuroResearch Clinics. The first of a series of papers by University of Minnesota Medical School based on the neurotransmitter testing research of NeuroResearch was published in "NeuroPsychiatric Disease and Treatment" May 1, 2009. Ingrid
Kohlstadt, MD of Johns Hopkins in her new
medical text book released February 7, 2009
included a chapter on depression written by
Marty L. Hinz, MD President Clinical
Research NeuroResearch Clinics outlining in
depth the proper use of amino acids and
neurotransmitter testing in treatment of
depression.
|
